Gene editing, or genome editing, is a type of genetic engineering in which with the help of engineered nucleases, DNA is inserted, deleted, or replaced in the genome of a living organism. These engineered nucleases, also known as molecular scissors, are the gene editing tools that are used to create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are then repaired through nonhomologous end joining or homologous recombination, resulting in targeted mutations. Such gene editing approach find its application in genetic engineering ranging from genetically modifying of plants for better quality to cure certain genetic disorders associated with animals and humans. Exhaustive research and development in genetic engineering has led to development of much powerful gene editing tools exhibiting high specificity, low off-target effects, and easy construction of DNA-binding domains. The emergence of these gene editing tools has resulted in significant interest in the biomedical community. CRISPR-Cas9is one of the gene editing tools, which has been gaining tremendous interest in the scientific community due to its faster, cheaper, more accurate, and more efficient application than the other existing gene editing tools.
The global gene editing tool market is expected to register a substantial growth in the near future attributed to rise in prevalence of cancer and genetic disorders such as sickle cell diseases, Alzheimer’s disease, and others, for which there are close to none or very limited therapy options available, along with other genetic and metabolic disorders such as diabetes, obesity, and others. In addition, increase in demand for genetically modified crops for agriculture is expected to drive the growth of the gene editing tool market. However, implementation of stringent regulations for the use of gene editing in crops for consumption and clinical use on humans restrains the growth of the market. On the contrary, potential applications for CRISPR-Cas9 gene therapy in human therapeutics as well as veterinary therapeutics are anticipated to provide lucrative opportunities for the growth of the market.
Recently, in December 2018, the U.S. FDA approved the treatment involving use of CRISPR-Cas9 gene editing tool for a study to treat a condition of a form of Leber congenital amaurosis, an inherited eye disorder that causes blindness due to a mutation in gene that affects the function of the retina. Editas Medicine, the company that is conducting the study along with Allergan, will be using an injection to directly deliver the treatment to the light-sensitive cells. The trial will enroll a total of 18 patients, both children (ages three and above) and adults.
The gene editing tool market is segmented on the basis of type, application, and end user. Based on type, the market is segmented into clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nuclease (TALEN), zinc finger nuclease (ZFN), and others. The applications covered in the study include clinical therapy, diagnostics, veterinary medicine, cell line engineering, bioremediation, food & brewing development, and others. By end user, the market is categorized into biotech & pharma companies, clinical research organizations, academic & research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The report provides a comprehensive analysis of the key players of the gene editing tool market are Thermo Fischer Scientific, Inc., Horizon Discovery Group plc, Merck KGaA, Genscript Biotech Corporation, Sangamo Therapeutics, Inc., Lonza Group AG, Editas Medicine, New England Biolabs, Origene Technologies, Inc., and CRISPR Therapeutics AG. Other players in the value chain include Transposagen Biopharmaceuticals, Inc., Integrated DNA Technologies, Inc., Takara Bio Inc., Intellia Therapeutics, and others.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current gene editing tool market trends and future estimations, which assists to identify the prevailing gene editing tool market opportunities.
- An in-depth market analysis includes various countries, and is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate country-specific plans.
- A comprehensive analysis of the factors that drives and restrains the growth of the global gene editing tool market is provided.
- Region-wise market conditions are comprehensively analyzed in this report.
- An extensive analysis of various countries provides insights that are expected to allow companies to strategically plan their business moves.
- Key market players within the gene editing tool market are profiled in this report and their strategies are analyzed thoroughly, which help to understand the competitive outlook of global gene editing tool market.
Gene Editing Tool Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Merck KGaA, CRISPR Therapeutics AG, Editas Medicine, Thermo Fischer Scientific Inc., Origene Technologies Inc., Genscript Biotech Corporation, Horizon Discovery Group plc, Lonza Group AG, New England Biolabs, Sangamo Therapeutics Inc. |
Loading Table Of Content...
